Results showed that pre-treatments with CSR (5, 10, 20, 40, 80 μM; 24 or 48 h) reduced the viability of IL-6/sIL-6R (100 ng/ml each)-stimulated RA-FLS in time- and dose-dependent manners (Fig. 1a). The gene discussed is IL6; the disease is rheumatoid arthritis.